Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mads M Helsted

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Diabetes, Obesity & Metabolism|October 10, 2025
Acute effects of GIP and GLP-1 receptor antagonism in totally pancreatectomized individuals: A randomized double-blind, placebo-controlled crossover studyLiva S L Krogh, Mads M Helsted, Anders Englund, et al.
The Lancet. Diabetes & Endocrinology|May 22, 2026
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trialMads M Helsted, Christiane Fonnesbech-Wulff, Nina L Schaltz, et al.
Diabetes|January 11, 2019
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy IndividualsLærke S Gasbjerg, Mads M Helsted, Bolette Hartmann, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Diabetes, Obesity & Metabolism|October 10, 2025
Acute effects of GIP and GLP-1 receptor antagonism in totally pancreatectomized individuals: A randomized double-blind, placebo-controlled crossover studyLiva S L Krogh, Mads M Helsted, Anders Englund, et al.
The Lancet. Diabetes & Endocrinology|May 22, 2026
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trialMads M Helsted, Christiane Fonnesbech-Wulff, Nina L Schaltz, et al.
Diabetes|January 11, 2019
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy IndividualsLærke S Gasbjerg, Mads M Helsted, Bolette Hartmann, et al.
Pageof 2